NCT01017536View on ClinicalTrials.gov

Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

May 31, 2012

Conditions
TuberculosisHIV Infections
Interventions
BIOLOGICAL

AERAS-402

AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.

BIOLOGICAL

Placebo

Placebo was the identical buffer solution in which AERAS-402 is formulated.

Trial Locations (1)

2570

Aurum Institute, Klerksdorp

Sponsors

Lead Sponsor

Aeras
All Listed Sponsors
collaborator

Crucell Holland BV

INDUSTRY

lead

Aeras

OTHER

NCT01017536 - Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults | Biotech Hunter | Biotech Hunter